Program status · reviewed 2026-09-11
What is planned, partnered, in research, or not offered.
Everything on this site carries a status. This is the ledger behind those labels: every pathway, every membership, every software feature and every research program, with what the label means.
33Planned
35Partner pathway
4Under review
9Research
3Not offered
What each label means
- Planned
- Planned program · launch and scope not yet confirmed
- Research
- Research concept · not a clinical service or enrollment offer
- Heritage
- Founder-reported heritage · inventory and deployed status to verify
- Partner pathway
- Proposed specialist or partner pathway · relationship not yet verified
- Validation pending
- Method validation and release status not documented
- Under review
- Under review · no current service or enrollment offer
- Not offered
- Not offered · retained to explain the scientific boundary
Pathways
84 pathways
| ID | Pathway | Track | Status | Availability |
|---|---|---|---|---|
| C01 | Preventive assessment & annual wellness | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C02 | Blood-pressure assessment & follow-up | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C03 | Lipid risk & familial cholesterol disorders | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C04 | Weight management & preservation of function | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C05 | Diabetes, prediabetes & selected glucose monitoring | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C06 | Kidney-risk assessment & co-management | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C07 | Metabolic liver health & specialist pathways | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C08 | Strength, mobility & falls prevention | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C09 | Bone health & fracture-risk review | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C10 | Sleep apnea, insomnia & coordinated sleep care | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C11 | Menopause & midlife health | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C12 | Men’s endocrine & sexual health | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C13 | Nutrition, deficiencies & supported activity | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C14 | Medication review & actionable pharmacogenomics | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C15 | Behavioral health & substance-use support links | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C16 | Vaccination & cancer-screening navigation | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C17 | Cognitive symptoms & memory-care coordination | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C18 | Long COVID & ME/CFS supportive care | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C19 | Orthostatic symptoms & dysautonomia assessment | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C20 | Rare-disease navigation & genetic counseling | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C21 | Autoimmune & inflammatory-disease coordination | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C22 | Recurrent infection & exposure-led infectious care | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C23 | Environmental & occupational exposure assessment | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C24 | Medically indicated replacement & hydration infusions | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C25 | Specialist injections, infusions & osteoporosis therapy | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C26 | Therapeutic phlebotomy for diagnosed conditions | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C27 | Wound & post-hospital care coordination | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C28 | Musculoskeletal pain & rehabilitation | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C29 | Remote physiologic monitoring | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C30 | Coordinated chronic & complex-care management | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C31 | Executive assessment & employer-supported prevention | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C32 | Selective lipoprotein apheresis pathway | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C33 | Therapeutic plasma exchange: established indications | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C34 | Plasma exchange: longevity & Long COVID questions | Research & concepts under review | Under review | Under review; no current clinical offer or enrollment. |
| C35 | Medical hyperbaric oxygen: indication-led access | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C36 | Hyperbaric oxygen: longevity & cognition questions | Research & concepts under review | Under review | Under review; no current clinical offer or enrollment. |
| C37 | Approved peptide & hormone medicines | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C38 | Medical-toxicology-directed chelation | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C39 | Rare-disease medicines & gene-therapy coordination | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C40 | Approved cellular therapy: specialist-center pathway | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C41 | Noninvasive photobiomodulation: defined uses | Care & clinical coordination | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| C42 | Selected PRP & musculoskeletal specialist procedures | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C43 | NAD+, glutathione & metabolic-infusion concepts | Research & concepts under review | Under review | Under review; no current clinical offer or enrollment. |
| C44 | DFPP, INUSpheresis & selective-filtration research | Research & concepts under review | Research | Research concept; no treatment booking or enrollment. |
| C45 | Somatic mitochondrial transfer & cellular-factory research | Research & concepts under review | Research | Research concept; no treatment booking or enrollment. |
| C46 | Intravenous multi-wavelength blood-laser concept | Research & concepts under review | Not offered | Not offered. Included to make the boundary clear. |
| C47 | EBOO / ozone blood-treatment concept | Research & concepts under review | Not offered | Not offered. Included to make the boundary clear. |
| C48 | Unapproved peptide & bioregulator research | Research & concepts under review | Research | Research concept; no treatment booking or enrollment. |
| C49 | Expanded cells, exosomes & engineered-product research | Research & concepts under review | Research | Research concept; no treatment booking or enrollment. |
| C50 | Genetic editing & AI-designed therapeutic discovery | Research & concepts under review | Research | Research concept; no treatment booking or enrollment. |
| C51 | Specialist neurostimulation pathways | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C52 | Extracorporeal photopheresis: specialist pathway | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| C53 | Primary FSGS: specialist apheresis assessment | Care & clinical coordination | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L01 | Blood counts & differential | Laboratory pathways | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| L02 | Routine chemistry & organ-function context | Laboratory pathways | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| L03 | Lipids, ApoB & Lp(a) | Laboratory pathways | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| L04 | Glucose, A1c & urinary albumin monitoring | Laboratory pathways | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| L05 | Thyroid, endocrine & nutritional tests | Laboratory pathways | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| L06 | Urinalysis, culture & susceptibility | Laboratory pathways | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L07 | Selected urinary molecular & AMR testing | Laboratory pathways | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| L08 | Women’s health, vaginitis & STI diagnostics | Laboratory pathways | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| L09 | Respiratory & gastrointestinal pathogen pathways | Laboratory pathways | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L10 | Actionable pharmacogenomics | Laboratory pathways | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| L11 | Definitive toxicology & therapeutic-drug measurements | Laboratory pathways | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L12 | Targeted steroid mass spectrometry | Laboratory pathways | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L13 | Clinical metals & trace elements | Laboratory pathways | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L14 | Targeted elemental speciation | Laboratory pathways | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L15 | Selected environmental biomonitoring | Laboratory pathways | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L16 | Biochemical-genetics measurements | Laboratory pathways | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L17 | Selected targeted lipidomic & ceramide panels | Laboratory pathways | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L18 | Inflammatory proteins, immune & autoimmune tests | Laboratory pathways | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L19 | Rare-disease & mitochondrial genetics | Laboratory pathways | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L20 | Hereditary cancer & precision-oncology coordination | Laboratory pathways | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L21 | Symptom-directed Alzheimer biomarkers | Laboratory pathways | Partner pathway | Proposed qualified-partner pathway; agreements and availability are not confirmed. |
| L22 | Microbiome & functional-gut research | Laboratory pathways | Research | Research concept; no treatment booking or enrollment. |
| L23 | Biological-age, epigenetic & telomere measurements | Laboratory pathways | Under review | Under review; no current clinical offer or enrollment. |
| L24 | Intracellular redox & mitochondrial-method research | Laboratory pathways | Research | Research concept; no treatment booking or enrollment. |
| L25 | Microplastics, nanoplastics & filtration-eluate research | Laboratory pathways | Research | Research concept; no treatment booking or enrollment. |
| L26 | Dry-disk & remote-sampling validation | Laboratory pathways | Research | Research concept; no treatment booking or enrollment. |
| L27 | Unvalidated detox & provoked-testing claims | Laboratory pathways | Not offered | Not offered. Included to make the boundary clear. |
| B01 | Terra industrial, materials & environmental analysis | Industrial analysis | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| B02 | Physician space & professional collaboration | Physician collaboration | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| S01 | Beyond Medical OS: internal workflow | Beyond Medical OS | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
| S02 | Beyond Medical OS: external collaboration | Beyond Medical OS | Planned | Planned pathway; staff, methods and service release remain to be confirmed. |
Memberships
| Program | Status | Pricing |
|---|---|---|
| Essential | Planned | On request; terms being finalised |
| Precision | Planned | On request; terms being finalised |
| Executive | Planned | On request; terms being finalised |
Instrument families
| Family | Status |
|---|---|
| Routine diagnostic analyzers | Planned |
| Molecular testing & qualified genomics partners | Planned |
| Liquid chromatography & mass spectrometry | Planned |
| X-ray diffraction | Heritage |
| Wavelength-dispersive X-ray fluorescence | Heritage |
| Ion chromatography | Heritage |
| Gas chromatography | Heritage |
| Programmed pyrolysis | Heritage |
| Titration & sample-preparation systems | Heritage |
Beyond Medical OS
| Capability | State | Milestone |
|---|---|---|
| Measurement & data lineage | Documented | Bind a reproducible clinical release to real instrument and laboratory interfaces. |
| Semantic & structural memory | Documented | Verify terminology, correction behavior and cross-store identity in an integrated pilot. |
| State & temporal memory | Prototype | Validate longitudinal reconciliation across actual clinical sources. |
| Spatial & geometric memory | Research | Ground each representation in measured data and test against an appropriate reference. |
| SE(3), D14 & typed representations | Documented | Version each schema, map its meaning and independently test transformations. |
| Fractal / holographic atomic memory | Research | Compare candidate retrieval, exact readback and independent checks against matched baselines. |
| Association, attractors & discovery | Research | Held-out evaluation, falsification tests and independent replication. |
| Physics-informed modeling & solvers | Research | Calibrate the model, quantify uncertainty and validate its intended use. |
| Literature & LLM assistance | Prototype | Evaluate retrieval coverage, source fidelity and errors in a defined workflow. |
| Clinical workflow & review | Prototype | Working interfaces, permissions, audit enforcement and a governed prospective pilot. |
Research programs
| Program | State |
|---|---|
| The cellular factory | Research |
| Mitochondria & cellular energy | Research |
| Light, lasers & activation compounds | Research |
| Gene & cell therapy pathways | Research |
| Novel peptide optimization | Research |
Questions about a status? Ask us directly.